These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Surgical and Molecular Pathology of Barrett Esophagus. Zibadi S; Coppola D Cancer Control; 2015 Apr; 22(2):177-85. PubMed ID: 26068762 [TBL] [Abstract][Full Text] [Related]
5. The Molecular Biologic Basis of Esophageal and Gastric Cancers. Pennathur A; Godfrey TE; Luketich JD Surg Clin North Am; 2019 Jun; 99(3):403-418. PubMed ID: 31047032 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Cronin J; McAdam E; Danikas A; Tselepis C; Griffiths P; Baxter J; Thomas L; Manson J; Jenkins G Am J Gastroenterol; 2011 Jan; 106(1):46-56. PubMed ID: 21157443 [TBL] [Abstract][Full Text] [Related]
7. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Lin J; Lin L; Thomas DG; Greenson JK; Giordano TJ; Robinson GS; Barve RA; Weishaar FA; Taylor JM; Orringer MB; Beer DG Clin Cancer Res; 2004 Sep; 10(17):5708-16. PubMed ID: 15355897 [TBL] [Abstract][Full Text] [Related]
8. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus]. Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. Farris AB; Demicco EG; Le LP; Finberg KE; Miller J; Mandal R; Fukuoka J; Cohen C; Gaissert HA; Zukerberg LR; Lauwers GY; Iafrate AJ; Mino-Kenudson M Am J Surg Pathol; 2011 May; 35(5):647-55. PubMed ID: 21422910 [TBL] [Abstract][Full Text] [Related]
11. Staging of early adenocarcinoma in Barrett's esophagus. Seerden TC; Larghi A Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):53-66. PubMed ID: 21112497 [TBL] [Abstract][Full Text] [Related]
12. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844 [TBL] [Abstract][Full Text] [Related]
13. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma. Wang XW; Gao HJ; Fang DC J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638 [TBL] [Abstract][Full Text] [Related]
14. Molecular staging of lymph nodes from patients with esophageal adenocarcinoma. Xi L; Luketich JD; Raja S; Gooding WE; Litle VR; Coello MC; Finkelstein SD; Chestney ML; Landreneau RJ; Hughes SJ; Godfrey TE Clin Cancer Res; 2005 Feb; 11(3):1099-109. PubMed ID: 15709177 [TBL] [Abstract][Full Text] [Related]
15. Lymphatic micrometastases in patients with early esophageal adenocarcinoma. Grotenhuis BA; van Heijl M; Wijnhoven BP; van Berge Henegouwen MI; Biermann K; ten Kate FJ; Busch OR; Dinjens WN; Tilanus HW; van Lanschot JJ J Surg Oncol; 2010 Dec; 102(7):863-7. PubMed ID: 20872812 [TBL] [Abstract][Full Text] [Related]
16. From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Saraggi D; Fassan M; Bornschein J; Farinati F; Realdon S; Valeri N; Rugge M Histol Histopathol; 2016 Jan; 31(1):25-32. PubMed ID: 26334343 [TBL] [Abstract][Full Text] [Related]